Calidi Biotherapeutics, Inc. (CLDI) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Win.
11/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseCLDI / S&P -28.87% / 15.20% |
LoseCLDI / S&P CLDI unavailable / 15.00% |
LoseCLDI / S&P -85.35% / 50.40% |
| 2026-Q11/3 |
LoseCLDI / S&P -79.57% / -4.33% |
LoseCLDI / S&P CLDI unavailable / 11.30% |
WinCLDI / S&P 69.62% / 27.70% |
| 2025-Q41/3 |
LoseCLDI / S&P -23.03% / 2.65% |
LoseCLDI / S&P CLDI unavailable / 9.00% |
WinCLDI / S&P 80.13% / 13.40% |
| 2025-Q31/3 |
LoseCLDI / S&P -44.93% / 8.12% |
LoseCLDI / S&P CLDI unavailable / 4.61% |
WinCLDI / S&P 22.49% / 13.45% |
| 2025-Q21/3 |
LoseCLDI / S&P -59.36% / 10.94% |
LoseCLDI / S&P CLDI unavailable / 4.83% |
WinCLDI / S&P 97.57% / 10.63% |
| 2025-Q11/3 |
LoseCLDI / S&P -50.78% / -4.27% |
LoseCLDI / S&P CLDI unavailable / 4.98% |
WinCLDI / S&P 31.56% / 10.57% |
| 2024-Q41/3 |
LoseCLDI / S&P 0.88% / 2.41% |
LoseCLDI / S&P CLDI unavailable / 5.25% |
WinCLDI / S&P 42.35% / 6.15% |
| 2024-Q31/3 |
LoseCLDI / S&P -43.00% / 5.89% |
LoseCLDI / S&P CLDI unavailable / 5.89% |
WinCLDI / S&P 112.36% / 6.11% |
| 2024-Q21/3 |
LoseCLDI / S&P -64.60% / 4.28% |
LoseCLDI / S&P CLDI unavailable / 5.38% |
WinCLDI / S&P 67.96% / 5.12% |
| 2024-Q10/3 |
LoseCLDI / S&P -62.58% / 10.56% |
LoseCLDI / S&P CLDI unavailable / 5.71% |
LoseCLDI / S&P CLDI unavailable / 5.59% |
| 2023-Q40/3 |
LoseCLDI / S&P -54.59% / 11.69% |
LoseCLDI / S&P CLDI unavailable / 6.81% |
LoseCLDI / S&P CLDI unavailable / 7.78% |
| 2023-Q30/3 |
LoseCLDI / S&P -68.30% / -3.27% |
LoseCLDI / S&P CLDI unavailable / 7.52% |
LoseCLDI / S&P CLDI unavailable / -5.03% |
| 2023-Q20/3 |
LoseCLDI / S&P 2.14% / 8.74% |
LoseCLDI / S&P CLDI unavailable / 9.50% |
LoseCLDI / S&P CLDI unavailable / -8.57% |
| 2023-Q10/3 |
LoseCLDI / S&P 0.98% / 7.50% |
LoseCLDI / S&P CLDI unavailable / 10.77% |
LoseCLDI / S&P CLDI unavailable / -15.69% |
| 2022-Q40/3 |
LoseCLDI / S&P 3.25% / 7.56% |
LoseCLDI / S&P CLDI unavailable / 11.88% |
LoseCLDI / S&P CLDI unavailable / -17.99% |
| 2022-Q31/3 |
WinCLDI / S&P -0.91% / -4.88% |
LoseCLDI / S&P CLDI unavailable / 13.47% |
LoseCLDI / S&P CLDI unavailable / -1.41% |
| 2022-Q21/3 |
WinCLDI / S&P 0.51% / -16.10% |
LoseCLDI / S&P CLDI unavailable / 13.71% |
LoseCLDI / S&P CLDI unavailable / 11.04% |
| 2022-Q11/3 |
WinCLDI / S&P 0.82% / -4.60% |
LoseCLDI / S&P CLDI unavailable / 15.97% |
LoseCLDI / S&P CLDI unavailable / 42.23% |
| 2021-Q40/3 |
LoseCLDI / S&P CLDI unavailable / 11.03% |
LoseCLDI / S&P CLDI unavailable / 15.00% |
LoseCLDI / S&P CLDI unavailable / 96.40% |
| 2021-Q30/3 |
LoseCLDI / S&P CLDI unavailable / 0.58% |
LoseCLDI / S&P CLDI unavailable / 10.77% |
LoseCLDI / S&P CLDI unavailable / 69.42% |
| 2021-Q20/3 |
LoseCLDI / S&P CLDI unavailable / 8.55% |
LoseCLDI / S&P CLDI unavailable / 6.58% |
LoseCLDI / S&P CLDI unavailable / 51.81% |
| 2021-Q10/3 |
LoseCLDI / S&P CLDI unavailable / 6.17% |
LoseCLDI / S&P CLDI unavailable / -1.06% |
LoseCLDI / S&P CLDI unavailable / 7.39% |
| 2020-Q40/3 |
LoseCLDI / S&P CLDI unavailable / 12.15% |
LoseCLDI / S&P CLDI unavailable / -3.72% |
LoseCLDI / S&P CLDI unavailable / -33.42% |
| 2020-Q30/3 |
LoseCLDI / S&P CLDI unavailable / 8.93% |
LoseCLDI / S&P CLDI unavailable / -2.04% |
LoseCLDI / S&P CLDI unavailable / -27.10% |
| 2020-Q20/3 |
LoseCLDI / S&P CLDI unavailable / 20.54% |
LoseCLDI / S&P CLDI unavailable / -0.46% |
LoseCLDI / S&P CLDI unavailable / -27.11% |
| 2020-Q10/3 |
LoseCLDI / S&P CLDI unavailable / -19.60% |
LoseCLDI / S&P CLDI unavailable / 3.47% |
LoseCLDI / S&P CLDI unavailable / -14.75% |
| 2019-Q40/3 |
LoseCLDI / S&P CLDI unavailable / 9.07% |
LoseCLDI / S&P CLDI unavailable / 5.36% |
LoseCLDI / S&P CLDI unavailable / 2.99% |
| 2019-Q30/3 |
LoseCLDI / S&P CLDI unavailable / 1.70% |
LoseCLDI / S&P CLDI unavailable / 5.02% |
LoseCLDI / S&P CLDI unavailable / 0.21% |
| 2019-Q20/3 |
LoseCLDI / S&P CLDI unavailable / 4.30% |
LoseCLDI / S&P CLDI unavailable / 6.64% |
LoseCLDI / S&P CLDI unavailable / 8.65% |
| 2019-Q10/3 |
LoseCLDI / S&P CLDI unavailable / 13.65% |
LoseCLDI / S&P CLDI unavailable / 8.12% |
LoseCLDI / S&P CLDI unavailable / 14.29% |
| 2018-Q40/3 |
LoseCLDI / S&P CLDI unavailable / -13.52% |
LoseCLDI / S&P CLDI unavailable / 9.05% |
LoseCLDI / S&P CLDI unavailable / 18.23% |
| 2018-Q30/3 |
LoseCLDI / S&P CLDI unavailable / 7.71% |
LoseCLDI / S&P CLDI unavailable / 10.21% |
LoseCLDI / S&P CLDI unavailable / 19.06% |
| 2018-Q20/3 |
LoseCLDI / S&P CLDI unavailable / 3.43% |
LoseCLDI / S&P CLDI unavailable / 9.03% |
LoseCLDI / S&P CLDI unavailable / 14.46% |
| 2018-Q10/3 |
LoseCLDI / S&P CLDI unavailable / -0.76% |
LoseCLDI / S&P CLDI unavailable / 7.68% |
LoseCLDI / S&P CLDI unavailable / 12.46% |
| 2017-Q40/3 |
LoseCLDI / S&P CLDI unavailable / 6.64% |
LoseCLDI / S&P CLDI unavailable / 7.03% |
LoseCLDI / S&P CLDI unavailable / 13.82% |
| 2017-Q30/3 |
LoseCLDI / S&P CLDI unavailable / 4.48% |
LoseCLDI / S&P CLDI unavailable / 5.68% |
LoseCLDI / S&P CLDI unavailable / 17.57% |
| 2017-Q20/3 |
LoseCLDI / S&P CLDI unavailable / 3.09% |
LoseCLDI / S&P CLDI unavailable / 4.83% |
LoseCLDI / S&P CLDI unavailable / 17.74% |
| 2017-Q10/3 |
LoseCLDI / S&P CLDI unavailable / 6.07% |
LoseCLDI / S&P CLDI unavailable / 3.67% |
LoseCLDI / S&P CLDI unavailable / 13.32% |
| 2016-Q40/3 |
LoseCLDI / S&P CLDI unavailable / 3.82% |
LoseCLDI / S&P CLDI unavailable / 2.09% |
LoseCLDI / S&P CLDI unavailable / 7.05% |
| 2016-Q30/3 |
LoseCLDI / S&P CLDI unavailable / 3.85% |
LoseCLDI / S&P CLDI unavailable / 0.20% |
LoseCLDI / S&P CLDI unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CLDI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -95.08% | 20.78% |
| Annualized return | -95.08% | 20.78% |
5Y · 2021-11-01 to 2026-08-27
| Metric | CLDI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.99% | 83.14% |
| Annualized return | -85.27% | 12.86% |
10Y · 2021-11-01 to 2026-08-27
| Metric | CLDI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.99% | 319.30% |
| Annualized return | -61.63% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |